Exosens Shares Drop 12.25% Over the Week and Enter Oversold Territory at €57.30
Exosens shares fell by 1.88% to €57.30 mid-morning, in an SBF 120 that lost 0.64% at 6,090.16 points. The specialist in night vision and imaging technologies for defense extends a downward trend that began last week. The weekly decline reaches 12.25%, but the annual performance remains positive at 64.18%.
A Tight Technical Setup Below the Lower Bollinger Band
The price has moved below the lower Bollinger band, set at €59.80, indicating an oversold signal after several sessions of decline. The RSI at 35 confirms the exhaustion of the selling trend, without yet triggering a rebound. The stock is now significantly below its 20 and 50-day moving averages, both around €64, representing a gap of approximately 11%. The 200-day moving average at €51.13 remains at a distance and represents a medium-term support. The technical support identified at €57.50 is in contact with the current price, making it the observed zone in the session.
A Clear Schedule and Tight Valuation
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
No publications are expected in the short term: the annual general meeting will be held on May 22, 2026, followed by the first-half results on July 28, 2026. The latest business update, published on April 29, reported a 19.7% increase in revenue for the first quarter, at €122.6 million. In terms of valuation, the stock is trading at about 30.5 times the expected earnings for the current fiscal year and 25.7 times those for the next fiscal year, compared to a sector average (Industrials) of 18.4 times. The expected growth in earnings per share from one year to the next is 18.4%. The stock is in the lower half of the SBF 120 this Tuesday, ranked 109th out of 120, without being among the index's sharpest declines. The next formal appointment: the general meeting on May 22.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
